Skip to main content


Latest articles

15-02-2019 | Rheumatology | News | Article

Longevity of hip, knee replacements in OA patients estimated

Two meta-analyses published in The Lancet provide estimates for how long hip and knee replacements are likely to last in patients with osteoarthritis.

14-02-2019 | Rheumatology | News | Article

No improvement in RA outcomes with SMS-enhanced monitoring

A Finnish trial has shown no significant improvement in the outcomes of patients with early rheumatoid arthritis who are monitored using an automated text message-enhanced approach versus the standard approach.

13-02-2019 | Rheumatology | News | Article

VTE risk elevated in patients with ankylosing spondylitis

Patients with ankylosing spondylitis have a significantly increased risk for venous thromboembolism compared with the general population, with the risk apparently highest in the first year after diagnosis, study findings indicate.

12-02-2019 | Rheumatology | Highlight | Article

Ibuprofen may be a ‘reasonable option’ for analgesia after hip replacement

Patients who are treated with ibuprofen alone experience comparable pain control in the first day after hip replacement to those give acetaminophen plus ibuprofen, findings from the PANSAID trial suggest.

11-02-2019 | Rheumatology | News | Article

Tocilizumab linked to elevated risk for some types of infection

Findings from a multi-database study suggest that rheumatoid arthritis patients treated with tocilizumab do not have a higher overall risk for serious infection than those treated with tumor necrosis factor inhibitors, but their risk for certain types of infection may be elevated.

08-02-2019 | Rheumatology | News | Article

Opioid use ‘alarmingly high’ among Swedish OA patients

Over a 1-year period, around one in four individuals with hip and/or knee osteoarthritis received opioids for pain management, compared with approximately one in 10 people without such a diagnosis, finds a Swedish population-based study.

08-02-2019 | Rheumatology | News | Article

PRO results back tofacitinib use in PsA patients

Two post-hoc analyses published in RMD Open indicate that treatment with the Janus kinase inhibitor tofacitinib is associated with an improvement in patient-reported outcomes among individuals with psoriatic arthritis.

07-02-2019 | Rheumatology | News | Article

Ixekizumab treatment linked to enthesitis, dactylitis improvements in PsA

A post-hoc analysis of the SPIRIT-P1 and SPIRIT-P2 trials suggests that treatment with ixekizumab is associated with improvements in enthesitis and dactylitis among patients with psoriatic arthritis.

07-02-2019 | Rheumatology | News | Article

MRI-guided treatment strategy unnecessary for RA in clinical remission

A magnetic resonance imaging-guided treat-to-target strategy does not improve disease activity or slow joint damage progression compared with a conventional strategy in patients with rheumatoid arthritis in clinical remission, research shows.

04-02-2019 | Rheumatology | News | Article

Add-on belimumab does not reduce relapse risk in ANCA-associated vasculitis

The addition of belimumab to maintenance therapy with azathioprine and low-dose glucocorticoids does not improve maintenance of remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, findings from the BREVAS trial suggest.

01-02-2019 | Rheumatology | News | Article

Unclear benefits of methotrexate highlighted for PsA patients

Findings from a systematic review suggest that methotrexate may offer some benefits for patients with psoriatic arthritis, but the quality of evidence is low.

31-01-2019 | Rheumatology | News | Article

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Patients with rheumatoid arthritis have better outcomes when treated with rituximab or tocilizumab than abatacept or tumor necrosis factor inhibitors, suggest the results from two real-world studies.

31-01-2019 | Rheumatology | News | Article

Tocilizumab, rituximab outperform other biologicals for RA

Findings from two registry-based studies suggest that tocilizumab and rituximab may be associated with better treatment outcomes than abatacept and tumour necrosis factor inhibitors among patients with rheumatoid arthritis.

30-01-2019 | Rheumatology | News | Article

Elevated fecal calprotectin linked to worse disease activity in axSpA

Elevated levels of fecal calprotectin, an indicator of gut inflammation, are associated with increased disease activity and reduced physical function in patients with axial spondyloarthritis, research shows.

29-01-2019 | Rheumatology | News | Article

IBD ‘uncommon’ in patients treated with secukinumab

Inflammatory bowel disease is an “uncommon” occurrence among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis who are treated with the interleukin-17A inhibitor secukinumab, researchers report.

28-01-2019 | Rheumatology | News | Article

Women with RA should expect a reduced success rate after assisted reproduction

Women with rheumatoid arthritis have a significantly lower chance of having a live birth following assisted reproductive technology treatment than women without RA, researchers report in the Annals of the Rheumatic Diseases.

25-01-2019 | Rheumatology | News | Article

Genomic analysis points to novel therapeutic targets for osteoarthritis

A genome-wide association study has identified novel genetic variants associated with osteoarthritis susceptibility, opening the path for the development of new drugs and repositioning of existing therapeutics.

24-01-2019 | Rheumatology | News | Article

Weight-loss diet beneficial for obese PsA patients

Targeting weight loss with a very-low-calorie diet may improve measures of disease activity among obese patients with psoriatic arthritis, researchers report.

24-01-2019 | Rheumatology | News | Article

Hydroxychloroquine–DMARD combination therapy supported for RA

Findings from a systematic review suggest that adding hydroxychloroquine to conventional DMARDs may improve clinical outcomes among patients with rheumatoid arthritis.

21-01-2019 | Rheumatology | News | Article

Trial results back TNF inhibitor dose-reduction strategy in ankylosing spondylitis patients

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

image credits